Role of SNARE proteins in tumourigenesis and their potential as targets for novel anti-cancer therapeutics

2015 ◽  
Vol 1856 (1) ◽  
pp. 1-12 ◽  
Author(s):  
Jianghui Meng ◽  
Jiafu Wang
Keyword(s):  
Cancer Therapeutics ◽  
Snare Proteins ◽  
Anti Cancer

Innovatory role of nanomaterials as bio-tools for treatment of cancer

2020 ◽  
Vol 0 (0) ◽  
Author(s):  
Khuram Shahzad Ahmad ◽  
Muntaha Talat ◽  
Shaan Bibi Jaffri ◽  
Neelofer Shaheen
Keyword(s):  
Cancer Treatment ◽  
Cancer Therapeutics ◽  
Physicochemical Characteristics ◽  
Global Scale ◽  
Current Review ◽  
Anti Cancer ◽  
Different Types ◽  
Cancerous Cells

AbstractConventional treatment modes like chemotherapy, thermal and radiations aimed at cancerous cells eradication are marked by destruction pointing the employment of nanomaterials as sustainable and auspicious materials for saving human lives. Cancer has been deemed as the second leading cause of death on a global scale. Nanomaterials employment in cancer treatment is based on the utilization of their inherent physicochemical characteristics in addition to their modification for using as nano-carriers and nano-vehicles eluted with anti-cancer drugs. Current work has reviewed the significant role of different types of nanomaterials in cancer therapeutics and diagnostics in a systematic way. Compilation of review has been done by analyzing voluminous investigations employing ERIC, MEDLINE, NHS Evidence and Web of Science databases. Search engines used were Google scholar, Jstore and PubMed. Current review is suggestive of the remarkable performance of nanomaterials making them candidates for cancer treatment for substitution of destructive treatment modes through investigation of their physicochemical characteristics, utilization outputs and long term impacts in patients.

The promise and current status of CDK12/13 inhibition for the treatment of cancer

2020 ◽  
Author(s):  
Solomon Tadesse ◽  
Derek R Duckett ◽  
Andrii Monastyrskyi
Keyword(s):  
Hepatocellular Carcinoma ◽  
Combination Therapy ◽  
Genomic Instability ◽  
Rational Design ◽  
Cancer Therapeutics ◽  
Current Status ◽  
Synthetic Lethal ◽  
Pancreatic Cancers ◽  
Anti Cancer

CDK12 and CDK13 are Ser/Thr protein kinases that regulate transcription and co-transcriptional processes. Genetic silencing of CDK12 is associated with genomic instability in a variety of cancers, including difficult-to-treat breast, ovarian, colorectal, brain and pancreatic cancers, and is synthetic lethal with PARP, MYC or EWS/FLI inhibition. CDK13 is amplified in hepatocellular carcinoma. Consequently, selective CDK12/13 inhibitors constitute powerful research tools as well as promising anti-cancer therapeutics, either alone or in combination therapy. Herein the authors discuss the role of CDK12 and CDK13 in normal and cancer cells, describe their utility as a biomarker and therapeutic target, review the medicinal chemistry optimization of existing CDK12/13 inhibitors and outline strategies for the rational design of CDK12/13 selective inhibitors.

Emerging role of terpenoids for the treatment of cancer: A review

2021 ◽  
Vol 21 ◽  
Author(s):  
Bhawna Chopra ◽  
Ashwani Kumar Dhingra ◽  
Kanaya Lal Dhar ◽  
Kunal Nepali
Keyword(s):  
Natural Products ◽  
Cancer Therapeutics ◽  
Literature Survey ◽  
Structure Activity ◽  
Anti Cancer ◽  
Systematic Structure ◽  
Pharmacological Potential ◽  
Systematic Identification ◽  
Cancer Activity

Aim: Terpenes are natural compounds found in several organisms belonging to the animal and plant kingdom, therefore, constitute the largest class of natural products and were a rich reservoir of candidate compounds for drug discovery. The review aims to focus on that the extensive is still needed to explore the anti-cancer components from natural products may led to the development of variety of derived terpenoidal moieties. Method: Literature survey has been carried out to determine the overwelhming potential of terpenoids. Results: The present article provides an overview of development of isoprene unit and the generation of the various types of terpenes which exhibits pharmacological potential. The anti-cancer activity of terpenoids appears promising and will potentially open more opportunities for cancer therapy. However, current studies are restricted to descriptive findings and some of them lack mechanistic insights and systematic structure--activity relationship studies. Future efforts into the systematic identification of the targets of terpenoids are believed to increase chances of gaining breakthrough insights in the field. Conclusion: There is still hope that new therapeutic options for the control of cancer and any other painful syndromes will be developed from terpenes, which were proved to be great candidates for cancer therapeutics.

scholarly journals Potential Role of Ginseng in the Treatment of Colorectal Cancer

2008 ◽  
Vol 36 (06) ◽  
pp. 1019-1028 ◽  
Author(s):  
Chong-Zhi Wang ◽  
Chun-Su Yuan
Keyword(s):  
Colorectal Cancer ◽  
Cancer Therapeutics ◽  
Chemotherapeutic Agents ◽  
Cancer Therapies ◽  
Chemical Structures ◽  
Time Treatment ◽  
Anti Cancer ◽  
The Us ◽  
Pharmacologically Active

Colorectal cancer remains one of the most prevalent cancer and a leading cause of cancer related death in the US. Many currently used chemotherapeutic agents are derived from botanicals. Identifying herbal sources, including those from ginseng family, to develop better anti-cancer therapies remains an essential step in advancing the treatment of the cancer. In this article, potential roles of ginseng herbs, especially American ginseng and notoginseng, in colorectal cancer therapeutics are presented. The major pharmacologically active constituents of ginsengs are ginsenosides, which can be mainly classified as protopanaxadiol and protopanaxatriol groups. Structure-activity relationship between their chemical structures and pharmacological activities are discussed. In addition, various steaming temperature and time treatment of the ginseng herbs can change ginsenoside profiles, and enhance their anti-cancer activities. This heat treatment process may increase the role of ginseng in treating colorectal cancer.

scholarly journals The role of the circadian clock in cancer hallmark acquisition and immune-based cancer therapeutics

2021 ◽  
Vol 40 (1) ◽  
Author(s):  
Elizabeth Cash ◽  
Sandra Sephton ◽  
Cassandra Woolley ◽  
Attia M. Elbehi ◽  
Anu R. I. ◽  
...  
Keyword(s):  
Adverse Effects ◽  
Paradigm Shift ◽  
Cancer Biology ◽  
Immune Cell ◽  
Checkpoint Inhibitors ◽  
Cancer Therapeutics ◽  
The Body ◽  
Anti Cancer ◽  
Biological Determinants

AbstractThe circadian system temporally regulates physiology to maintain homeostasis. Co-opting and disrupting circadian signals appear to be distinct attributes that are functionally important for the development of a tumor and can enable or give rise to the hallmarks that tumors use to facilitate their initiation, growth and progression. Because circadian signals are also strong regulators of immune cell proliferation, trafficking and exhaustion states, they play a role in how tumors respond to immune-based cancer therapeutics. While immuno-oncology has heralded a paradigm shift in cancer therapeutics, greater accuracy is needed to increase our capability of predicting who will respond favorably to, or who is likely to experience the troubling adverse effects of, immunotherapy. Insights into circadian signals may further refine our understanding of biological determinants of response and help answer the fundamental question of whether certain perturbations in circadian signals interfere with the activity of immune checkpoint inhibitors. Here we review the body of literature highlighting circadian disruption as a cancer promoter and synthesize the burgeoning evidence suggesting circadian signals play a role in how tumors respond to immune-based anti-cancer therapeutics. The goal is to develop a framework to advance our understanding of the relationships between circadian markers, cancer biology, and immunotherapeutics. Bolstered by this new understanding, these relationships may then be pursued in future clinical studies to improve our ability to predict which patients will respond favorably to, and avoid the adverse effects of, traditional and immune-based cancer therapeutics.

scholarly journals Non-cancer to anti-cancer: investigation of human ether-a-go-go-related gene potassium channel inhibitors as potential therapeutics

2021 ◽  
Vol 33 (1) ◽  
Author(s):  
Vaishali M. Patil ◽  
Anand Gaurav ◽  
Priyanka Garg ◽  
Neeraj Masand
Keyword(s):  
Cancer Cells ◽  
Preliminary Investigation ◽  
Drug Repurposing ◽  
Cancer Therapeutics ◽  
Late Stage Cancer ◽  
Anti Cancer ◽  
Reported Study ◽  
Binding Pockets ◽  
Cancer Inhibition

Abstract Background The expression of hERG K+ channels is observed in various cancer cells including epithelial, neuronal, leukemic, and connective tissue. The role of hERG potassium channels in regulating the growth and death of cancer cells include cell proliferation, survival, secretion of proangiogenic factors, invasiveness, and metastasis. Methods In the reported study, an attempt has been made to investigate some non-cancer hERG blockers as potential cancer therapeutics using a computational drug repurposing strategy. Preliminary investigation for hERG blockers/non-blockers has identified 26 potential clinically approved compounds for further studies using molecular modeling. Results The interactions at the binding pockets have been investigated along with the prioritization based on the binding score. Some of the identified potential hERG inhibitors, i.e., Bromocriptine, Darglitazone, and Troglitazone, have been investigated to derive the mechanism of cancer inhibition. Conclusions The proposed mechanism for anti-cancer properties via hERG blocking for some of the potential compounds is required to be explored using other experimental methodologies. The drug repurposing approach applied to investigate anti-cancer therapeutics may direct to provide a therapeutic solution to late-stage cancer and benefit a significant population of patients.

Resveratrol: A new potential therapeutic agent for melanoma?

2019 ◽  
Vol 26 ◽  
Author(s):  
Mohamad Hossein Pourhanifeh ◽  
Kazem Abbaszadeh-Goudarzi ◽  
Mohammad Goodarzi ◽  
Sara G.M. Piccirillo ◽  
Alimohammad Shafiee ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Therapeutic Agent ◽  
Current Knowledge ◽  
Treatment Resistance ◽  
Anti Cancer ◽  
Apoptosis Inducer ◽  
Life Threatening ◽  
First Time

: Melanoma is the most life-threatening and aggressive class of skin malignancies. The incidence of melanoma has steadily increased. Metastatic melanoma is greatly resistant to standard anti-melanomatreatments such as chemotherapy, and 5-year survival rate of cases with melanoma who have metastatic form of disease is less than 10%. The contributing role of apoptosis, angiogenesis and autophagy in the pathophysiology of melanoma has been previously demonstrated. Thus, it is extremely urgent to search for complementary therapeutic approachesthat couldenhance the quality of life of subjects and reduce treatment resistance and adverse effects. Resveratrol, known as a polyphenol component present in grapes and some plants, has anti-cancer properties due to its function as an apoptosis inducer in tumor cells, and anti-angiogenic agent to prevent metastasis. However, more clinical trials should be conducted to prove resveratrol efficacy. : Herein, for first time, we summarize current knowledge of anti-cancerous activities of resveratrol in melanoma.

Sign in / Sign up

Export Citation Format

Share Document